<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Target levels of ex vivo inhibition of platelet aggregation (<z:chebi fb="23" ids="17824,30802">IPA</z:chebi>) induced by <z:chebi fb="3" ids="16335">adenosine</z:chebi> <z:chebi fb="2" ids="18361">diphosphate</z:chebi> (<z:chebi fb="13" ids="16761">ADP</z:chebi>) that produce clinically relevant effects of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi>, a P2Y12 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, are unclear </plain></SENT>
<SENT sid="1" pm="."><plain>We examined standard and modified <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> and P2Y12 receptor occupancy as predictors of antithrombotic (% <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> weight reduction) and <z:mp ids='MP_0001914'>bleeding</z:mp> time (BT, fold-increase over control) effects of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> in rabbit models of carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> and cuticle <z:mp ids='MP_0001914'>bleeding</z:mp>, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>Standard and modified <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> with 20 microM <z:chebi fb="13" ids="16761">ADP</z:chebi> were measured in the absence and presence of partial P2Y1 blockade, respectively </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="37941">Clopidogrel</z:chebi> maximally produced standard <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> of 57% +/- 5%, antithrombotic effect of 85% +/- 1%, BT increase of 6.0 +/- 0.4-fold and P2Y12 receptor occupancy of 87% +/- 5% </plain></SENT>
<SENT sid="4" pm="."><plain>Surprisingly, a <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> dose that produced a low standard <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> of 17% +/- 4% and P2Y12 receptor occupancy of 39% +/- 5% achieved a significant antithrombotic activity of 55% +/- 2% with a moderate increase in BT of 2.0 +/- 0.1-fold </plain></SENT>
<SENT sid="5" pm="."><plain>This underestimation of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> efficacy by standard <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> was improved by measuring either modified <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> or P2Y12 receptor occupancy </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that in <z:chebi fb="0" ids="37941">clopidogrel</z:chebi>-treated rabbits, low standard <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> is associated with significant antithrombotic effects </plain></SENT>
<SENT sid="7" pm="."><plain>Moreover, modified <z:chebi fb="23" ids="17824,30802">IPA</z:chebi> and P2Y12 receptor occupancy appear to better predict the magnitude of <z:chebi fb="0" ids="37941">clopidogrel</z:chebi>'s efficacy compared with standard <z:chebi fb="23" ids="17824,30802">IPA</z:chebi>, which may be a better predictor of BT </plain></SENT>
</text></document>